Long-term Efficacy and Safety of Sitagliptin in Elderly Patients with Type 2 Diabetes Mellitus
| Autor: | Motofumi Sasaki, Ken-ichiro Tanaka, Masakazu Notsu, Yuko Tada, Toshitsugu Sugimoto, Ippei Kanazawa, Nobuaki Kiyohara |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty Time Factors endocrine system diseases medicine.drug_class Aspartate transaminase 030209 endocrinology & metabolism Type 2 diabetes Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine Diabetes mellitus Internal Medicine medicine Humans Hypoglycemic Agents 030212 general & internal medicine Aged Retrospective Studies Glycemic Glycated Hemoglobin Dose-Response Relationship Drug biology business.industry Sitagliptin Phosphate nutritional and metabolic diseases Type 2 Diabetes Mellitus General Medicine medicine.disease Sulfonylurea Treatment Outcome Diabetes Mellitus Type 2 Alanine transaminase Sitagliptin biology.protein Female business Follow-Up Studies medicine.drug |
| Zdroj: | Internal Medicine. 55:1275-1278 |
| ISSN: | 1349-7235 0918-2918 |
| DOI: | 10.2169/internalmedicine.55.6011 |
| Popis: | Objective We herein conducted a retrospective study to evaluate the long-term efficacy and safety of sitagliptin treatment in elderly patients with type 2 diabetes mellitus. Methods We analyzed the changes in glycemic control in 112 Japanese type 2 diabetes patients over 65 years of age treated with 50 mg/day sitagliptin. Hemoglobin A1c (HbA1c) levels, liver and kidney functions, and usage of hypoglycemic agents were recorded for 24 months. Results HbA1c levels were significantly decreased, and the significance of HbA1c reduction was maintained during the observation period [from 7.7±1.1% to 7.2±0.7% (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|